NCT03249714View on ClinicalTrials.gov

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 26, 2019

Study Completion Date

July 29, 2020

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Ofatumumab

Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)

DRUG

Matching placebo of ofatumumab

Matching placebo in pre-filled syringes

Trial Locations (14)

420021

Novartis Investigative Site, Kazan'

630007

Novartis Investigative Site, Novosibirsk

791-0295

Novartis Investigative Site, Tōon

812-8582

Novartis Investigative Site, Fukuoka

063-0005

Novartis Investigative Site, Sapporo

020-8505

Novartis Investigative Site, Morioka

980 8574

Novartis Investigative Site, Sendai

983 8512

Novartis Investigative Site, Sendai

350 8550

Novartis Investigative Site, Kawagoe

187-8551

Novartis Investigative Site, Kodaira

160 8582

Novartis Investigative Site, Shinjuku-ku

260 8677

Novartis Investigative Site, Chiba

951 8520

Novartis Investigative Site, Niigata

556-0016

Novartis Investigative Site, Osaka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY